When a Long Shot is Worth a Shot  

Oleh:

Jacobs, Tom ; Fischer, Jeff

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 7 (Jul. 2005), page 805-806.
Topik: biotechnology; a long shot; worth a shot

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.3 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Biotech speculators cave newer, productless and profitless companies with exciting late stage, high potential product candidates. But with information today so easy to come by, no candidate remains hidden for long. That's why it's both a mystery and a delight to find an unknown biotech speculation. Indeed, northfield laboratories (northfield, IL, USA, Nasdaq, NFLD), has received scant attention. Despite its potential billion dollar a year blood substitute in pivotal phase 3 trials in the united states, the company is valued at a paltry US$ 260 million. It's a speculation for sure everything depends on regulatory approval, but the possible payoff from northfield's success is so great that this is one of those rate times when a careful speculation may be worth the risk of loss.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali